NCT05291689 - A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

October 18, 2023

Study Completion Date

February 19, 2025

Conditions

Inflammatory Bowel DiseasesColitis, Ulcerative

Interventions

DRUG

MORF-057

MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Trial Locations (17)

10075

Clinical Study Site, New York

11235

Clinical Study Site, Brooklyn

33609

Clinical Study Site, Tampa

70503

Clinical Study Site, Lafayette

07728

Clinical Study Site, Freehold

85-794

Clinical Study Site, Bydgoszcz

82-300

Clinical Study Site, Elblag

40-748

Clinical Study Site, Katowice

90-349

Clinical Study Site, Lodz

90-752

Clinical Study Site, Lodz

32-600

Clinical Study Site, Oświęcim

81-756

Clinical Study Site, Sopot

41-209

Clinical Study Site, Sosnowiec

28-200

Clinical Study Site, Staszów

43-100

Clinical Study Site, Tychy

00-728

Clinical Study Site, Warsaw

02-665

Clinical Study Site, Warsaw

All Listed Sponsors

lead

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

INDUSTRY